• 1. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

Introduction to 6-Methoxyquinoline-2-carbonitrile (CAS No. 5467-79-8)

6-Methoxyquinoline-2-carbonitrile, with the chemical formula C₁₀H₆N₂O, is a heterocyclic organic compound belonging to the quinoline family. This compound has garnered significant attention in the field of pharmaceutical chemistry and medicinal research due to its versatile structural framework and potential biological activities. The presence of both a methoxy group and a nitrile group in its molecular structure imparts unique reactivity and functional properties, making it a valuable intermediate in the synthesis of various pharmacologically active molecules.

The CAS No. 5467-79-8 uniquely identifies this compound in scientific literature and industrial applications, ensuring precise referencing and consistency across different research groups and manufacturing processes. As a derivative of quinoline, 6-Methoxyquinoline-2-carbonitrile inherits several desirable characteristics, such as stability under moderate conditions and compatibility with multiple synthetic pathways. These attributes have positioned it as a key building block in the development of novel therapeutic agents.

In recent years, the pharmaceutical industry has witnessed an increasing demand for quinoline derivatives due to their demonstrated efficacy against a range of diseases. Among these derivatives, 6-Methoxyquinoline-2-carbonitrile has been extensively studied for its potential applications in antimalarial, antibacterial, and anticancer therapies. The nitrile group in its structure serves as a versatile handle for further functionalization, enabling the synthesis of more complex molecules with enhanced biological activity.

One of the most compelling aspects of 6-Methoxyquinoline-2-carbonitrile is its role as a precursor in the synthesis of small-molecule inhibitors targeting specific enzymatic pathways involved in disease progression. For instance, recent studies have highlighted its utility in generating compounds that modulate kinases and other critical enzymes implicated in cancer metabolism. The methoxy substituent at the 6-position enhances lipophilicity while maintaining solubility, making it an ideal candidate for drug-like properties optimization.

The chemical synthesis of 6-Methoxyquinoline-2-carbonitrile typically involves multi-step reactions starting from readily available quinoline precursors. Advanced synthetic methodologies, such as palladium-catalyzed cross-coupling reactions and nucleophilic substitutions, have been employed to achieve high yields and purity levels. These synthetic strategies not only facilitate large-scale production but also allow for structural modifications to tailor the compound’s biological profile.

From a medicinal chemistry perspective, 6-Methoxyquinoline-2-carbonitrile has been incorporated into several drug candidates that are currently undergoing preclinical evaluation. Its structural motif is particularly relevant in designing molecules that interact with nucleic acid-binding proteins or membrane receptors. The electron-withdrawing nature of the nitrile group enhances binding affinity, while the methoxy group contributes to metabolic stability.

The growing interest in natural product-inspired drug discovery has also led to investigations into derivatives of 6-Methoxyquinoline-2-carbonitrile that mimic bioactive scaffolds found in plants and microorganisms. By leveraging computational chemistry tools and high-throughput screening techniques, researchers have identified novel analogs with improved pharmacokinetic profiles. These efforts underscore the compound’s significance as a scaffold for developing next-generation therapeutics.

In conclusion, 6-Methoxyquinoline-2-carbonitrile (CAS No. 5467-79-8) represents a structurally intriguing and biologically relevant compound with broad applications in pharmaceutical research. Its unique combination of functional groups makes it an indispensable tool for medicinal chemists seeking to design innovative treatments for various diseases. As research continues to uncover new synthetic pathways and biological functions, this compound is poised to remain at the forefront of drug discovery efforts.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)